Study of GS-0415 for People Living with HIV
Part of Infections clinical trials.
This trial tests a new medicine, GS-0415, for people with HIV who are already on a stable treatment plan. It aims to see how safe and effective the new medicine is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been on the same HIV treatment for at least 12 months.
- Your current HIV treatment does not include maraviroc, enfuvirtide, ibalizumab, or fostemsavir.
- Your viral load (amount of HIV in your blood) has been undetectable (below 50 copies) for the past 12 months, including at screening.
- Your CD4 count (a measure of immune system health) is at least 350.
- You weigh between 50 kg (110 lbs) and 110 kg (242 lbs), and your body mass index (BMI) is between 18.5 and 35.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody called BNT351 to see if it is safe and how it affects the immune system. It is for adults who either do not have HIV, or have HIV and are not currently on HIV medications.
This Phase 3 study tests UB-421 added to a customized (optimized) set of existing HIV medicines for people with HIV that is resistant to multiple drugs. It may help reduce the virus more effectively when standard treatments have not been enough.
This study tests a new injectable drug (VH4011499) for safety and how the body processes it. It's for healthy adults without HIV, and participants will get either the study drug or a placebo (an inactive shot).
This study tests a new vaccine designed to help your immune system fight HIV better. It is for people with HIV who are already on effective antiretroviral therapy and have a well-controlled virus. The goal is to see if the vaccine is safe and boosts your body's natural defenses.
This study tests a new long-acting medicine that may help prevent HIV. It is given as an injection, and the study checks how safe it is and how it works in healthy volunteers.
This is an early-stage safety study testing a new investigational drug (VH4770359) in healthy volunteers. Researchers want to understand how the body processes the drug and ensure it is safe and well-tolerated.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.